GSK’s RSV shot gets FDA advisers’ backing on safety for older people
A unanimous panel advising the US drug authority says GSK’s data shows its RSV vaccine is effective – but not all panel members were convinced of its safety.
By Lisa Pham and Tanaz Meghjani, bloomberg
GSK Plc’s vaccine for respiratory syncytial virus won the support of a key panel of US regulatory advisers for use in people 60 and older, as the drugmaker races against Pfizer Inc. to bring to market the first vaccine for RSV.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg&w=384&q=75)
